HIV News and Research RSS Feed - HIV News and Research

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan announces U.S. launch of Prednisolone Sodium Phosphate Orally Disintegrating Tablets

Mylan Inc. today announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. [More]
Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan introduces Methocarbamol Injection USP, 100 mg/mL in the U.S.

Mylan Inc. today announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. [More]
Smaller blood transfusions during surgeries better for patients with heart disease

Smaller blood transfusions during surgeries better for patients with heart disease

Patients with heart disease who receive transfusions during surgeries do just as well with smaller amounts of blood and face no greater risk of dying from other diseases than patients who received more blood, according to a new Rutgers study. [More]
Research finding could lead to development of effective vaccines against microbial infections

Research finding could lead to development of effective vaccines against microbial infections

The diverse functions of a special cell-recognition lipoprotein, LOX-1, weren't always fully understood. However, Baylor Research Institute investigators gained better insight into LOX-1's role in immune responses through a study recently published in Immunity. Investigators found that the lipoprotein promotes humoral responses, which could allow researchers to design effective vaccines against microbial infections, including influenza viruses and HIV. [More]
Potential new active substances for treating dengue virus

Potential new active substances for treating dengue virus

Researchers from Johannes Gutenberg University Mainz and the Julius Maximilian University of Würzburg are proposing potential new active substances for treating the dengue virus. Just like Ebola, dengue fever is also caused by a virus for which there is currently no cure and no vaccine and can be fatal. [More]
Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

Added benefit of daclatasvir drug not proven for chronic hepatitis C infection

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy. [More]
Mylan announces U.S. launch of Celecoxib Capsules

Mylan announces U.S. launch of Celecoxib Capsules

Mylan Inc. today announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. [More]
Treatment guidelines lacking for Ebola patients, say infectious diseases experts

Treatment guidelines lacking for Ebola patients, say infectious diseases experts

As the Ebola Virus Diseases (EVD) epidemic continues to rage in West Africa, infectious diseases experts call attention to the striking lack of treatment guidelines. With over 16,000 total cases and more than 500 new infections reported per week, and probable underreporting of both cases and fatalities, the medical community still does not have specific approved treatment in place for Ebola, according to an editorial published in the International Journal of Infectious Diseases. [More]
Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm. [More]
Drug proves effective at inhibiting growth of drug-resistant bacteria

Drug proves effective at inhibiting growth of drug-resistant bacteria

A treatment pioneered at the University of Pittsburgh Center for Vaccine Research is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called "superbugs" resistant to almost all existing antibiotics, which plague hospitals and nursing homes. [More]
Cannabis Science, CFA partner to improve health-related education infrastructure in Africa

Cannabis Science, CFA partner to improve health-related education infrastructure in Africa

Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its President & CEO, Mr. Raymond C. Dabney, along with CBIS's Senior Scientific Advisor, Dr. Roscoe M. Moore, Jr., have initiated a partnership between CBIS and the Constituency for Africa to help improve the healthcare and health-related education infrastructure in Africa. [More]
Alere Determine HIV-1/2 Ag/Ab Combo test receives CLIA Waiver from FDA

Alere Determine HIV-1/2 Ag/Ab Combo test receives CLIA Waiver from FDA

Alere Inc., a global leader in rapid diagnostic tests, today announced that the U.S. Food and Drug Administration (FDA) has granted CLIA (Clinical Laboratory Improvement Amendments) Waiver for the Alere Determine™ HIV-1/2 Ag/Ab Combo test. [More]
Study: Injectable 3D vaccines could help prevent cancer, infectious disease

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. [More]
Verizon announces winners of 2014 Powerful Answers Award

Verizon announces winners of 2014 Powerful Answers Award

The wait is over. Verizon is proud to announce the winners of Verizon's 2014 Powerful Answers Award, three in each of the following categories: education, health care, sustainability and transportation. [More]
New diagnostic system describes symptoms using the image of patient's tongue

New diagnostic system describes symptoms using the image of patient's tongue

Physicians often ask their patients to "Please stick out your tongue". The tongue can betray signs of illness, which combined with other symptoms such as a cough, fever, presence of jaundice, headache or bowel habits, can help the physician offer a diagnosis. For people in remote areas who do not have ready access to a physician, a new diagnostic system is reported in the International Journal of Biomedical Engineering and Technology that works to combine the soft inputs of described symptoms with a digital analysis of an image of the patient's tongue. [More]
New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Study sheds light on common psychosocial barriers affecting HPV vaccination in Puerto Rico

Study sheds light on common psychosocial barriers affecting HPV vaccination in Puerto Rico

Young Puerto Rican women and their mothers know little about the human papillomavirus (HPV) and cervical cancer, according to researchers at The University of Texas Health Science Center at Houston School of Public Health. [More]
Jakafi receives expanded approval from FDA for use in treatment of polycythemia vera

Jakafi receives expanded approval from FDA for use in treatment of polycythemia vera

Diplomat Pharmacy, Inc., the nation's largest independent specialty pharmacy, announced that the U.S. Food and Drug Administration has approved an expanded indication of Jakafi (ruxolitinib). [More]
New study investigates rate of HIV testing in patients with mental illnesses

New study investigates rate of HIV testing in patients with mental illnesses

People with mental illness are more likely to have been tested for HIV than those without mental illness, according to a new study from a team of researchers at Penn Medicine and the U.S. Centers for Disease Control and Prevention published online this week in AIDS Patient Care and STDs. [More]
Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan gets tentative approval from FDA for two pediatric dosages of abacavir/lamivudine tablets

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration for its New Drug Applications (NDAs) for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. [More]